Clinical Trials Detail

Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer After Surgery

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Objective
CategoryInformation
Study #: A081105 - Alchemist
Anatomic Site: Lung
Histology: non-squamous non-small cell lung cancer (NSCLC)
Mutation: EGFR positive (exon 19 deletion; L858R mutation)
Stage: Stage IB (with tumor size >4cm) - IIIA
Treatment Phase: Previously registered to A151216 with an EGFR exon 19 deletion or L858R mutation, have complete recovery from surgery with negative margins and standard post-operative therapy.
Location:
Study Link: hthttps://clinicaltrials.gov/ct2/show/NCT02193282?term=A081105&rank=2

Clinical Trial Categories

  • Lung